Page last updated: 2024-08-24

tolafentrine and zardaverine

tolafentrine has been researched along with zardaverine in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hatzelmann, A; Schudt, C; Tenor, H	1
Enke, B; Ghofrani, HA; Grimminger, F; Schermuly, RT; Schudt, C; Seeger, W; Walmrath, D; Weissmann, N	1

Other Studies

2 other study(ies) available for tolafentrine and zardaverine

Article	Year
Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. British journal of pharmacology, 1995, Volume: 114, Issue:4 Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Antagonists; Benzamides; Blood Proteins; Cell Separation; Complement C5a; Cyclic Nucleotide Phosphodiesterases, Type 4; Electromagnetic Fields; Eosinophil Granule Proteins; Eosinophil-Derived Neurotoxin; Eosinophils; Humans; Inflammation Mediators; Luminescent Measurements; Naphthyridines; Neurotoxins; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyridazines; Pyridines; Pyrrolidinones; Ribonuclease, Pancreatic; Ribonucleases; Rolipram; Theophylline	1995
Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. American journal of respiratory and critical care medicine, 1999, Volume: 160, Issue:5 Pt 1 Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Administration, Inhalation; Aerosols; Animals; Antihypertensive Agents; Blood Pressure; Cardiac Output; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epoprostenol; Hypertension, Pulmonary; Naphthyridines; Phosphodiesterase Inhibitors; Pulmonary Circulation; Purinones; Pyridazines; Rabbits; Rolipram; Vasoconstrictor Agents; Vasodilation	1999

Article

Year

Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions.

British journal of pharmacology, 1995, Volume: 114, Issue:4

Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Antagonists; Benzamides; Blood Proteins; Cell Separation; Complement C5a; Cyclic Nucleotide Phosphodiesterases, Type 4; Electromagnetic Fields; Eosinophil Granule Proteins; Eosinophil-Derived Neurotoxin; Eosinophils; Humans; Inflammation Mediators; Luminescent Measurements; Naphthyridines; Neurotoxins; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyridazines; Pyridines; Pyrrolidinones; Ribonuclease, Pancreatic; Ribonucleases; Rolipram; Theophylline

1995

Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension.

American journal of respiratory and critical care medicine, 1999, Volume: 160, Issue:5 Pt 1

Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Administration, Inhalation; Aerosols; Animals; Antihypertensive Agents; Blood Pressure; Cardiac Output; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epoprostenol; Hypertension, Pulmonary; Naphthyridines; Phosphodiesterase Inhibitors; Pulmonary Circulation; Purinones; Pyridazines; Rabbits; Rolipram; Vasoconstrictor Agents; Vasodilation

1999